EV/EBITDA Multiple: MangoRx (MGRX)

MGRX (MangoRx) - company brandmark

Mangoceuticals, Inc. (MGRX) is developing a digital ecosystem for men's health, where the pricing strategy is based on premium service and efficient logistics. Business growth relies on brand recognition and the optimization of user acquisition costs. The current EV/EBITDA multiple is 0.00. The available price action vector confirms the stability of the IT infrastructure, which operates via scalable cloud solutions without vendor lock-in risks.

MGRX Mangoceuticals: Enterprise Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/11/2026

MGRX (mangorx.com): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart Mangoceuticals|MGRX - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization Mangoceuticals, Inc.|MGRX - Enterprise Value
- issuer book value statistics:
Net Assets per Single Share Mangoceuticals|MGRX - Accounting Capitalization|Market Capitalization to Book Value Ratio mangorx.com|MGRX - Company Balance Sheet Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Mangoceuticals, Inc.|MGRX - Long-Term Liabilities to Capital|Short-Term Debt to Capital Mangoceuticals|MGRX - Company Total Debt|Debts to Book Capitalization Mangoceuticals, Inc.|MGRX - Long-Term Debt|Company Current Liabilities Mangoceuticals|Quick Liquidity Indicator mangorx.com
- business earnings and investment ratios data:
MGRX - Profit After Payment of Taxes|Projected Future Earnings Mangoceuticals, Inc.|MGRX - Business Payback Period|Forward P/E Multiple Mangoceuticals|MGRX - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Mangoceuticals, Inc.|MGRX - Operating profit EBITDA|Earnings per share for the last twelve months Mangoceuticals|MGRX - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months mangorx.com|MGRX - Expected net earnings per share growth this year|Expected earnings per share growth for next year Mangoceuticals, Inc.
Analysis of all company metrics:MangoRx MGRX
Original product of mangorx.com

Amid aggressive dumping by Mangoceuticals, Inc. (MGRX) in the telemedicine sector, this indicator becomes a critical tool for monitoring operational efficiency and debt load. By analyzing the company's EV/EBITDA multiple over time, investors assess the total enterprise value relative to earnings before interest, taxes, depreciation, and amortization, which helps identify hidden risks of margin compression resulting from marketing wars with market behemoths.

Competitor analysis

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Hims HIMS|HNGE - Enterprise Value to EBITDA Ratio|Teladoc Health, Inc. - EV/EBITDA Multiple|TALK - EV/EBITDA Multiple|lifemd.com (LFMD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation AMWL|DRIO (DarioHealth Corporation) - EV/EBITDA Multiple|VSEE - Enterprise Value to EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Mobile-health (MNDR)|ACCD - Company Value to EBITDA|EV/EBITDA Multiple BTCY (Biotricity)|LYT - Enterprise Value to EBITDA Ratio|Catasys - EV/EBITDA Multiple|Company Value to EBITDA SHL Telemedicine Ltd.|THRN (Thorne HealthTech) - Enterprise Value to EBITDA Ratio